B细胞淋巴瘤因子9的表达与前列腺癌临床病理参数及患者生存的关系

Association of BCL9 expression with prostate cancer clinicopathological features and survival

目的 探讨B细胞淋巴瘤因子9（BCL9）作为Wnt信号通路的核内元件,它在β-链蛋白（β-catenin）的转录中的重要作用.观察BCL9在前列腺癌细胞中的表达、其参与的发病进程及临床预后的作用.方法 采用免疫组化检测98例前列腺癌患者及20例良性前列腺增生患者BCL9的表达水平.χ^2检验分析BCL9表达同前列腺癌患者临床病理参数的关系.Kaplan-Meier生存曲线及log-rank统计方法计算BCL9表达同前列腺癌生化复发发病进程的关系.Cox多因素回归模型检测BCL9表达预测前列腺癌生化复发的危险度情况.结果 BCL9在前列腺癌组中阳性率为53.1％（52/98）,在良性组织的阳性率为25.0％ （5/20）,两者差异有统计学意义（P =0.022）.BCL9表达同前列腺癌Gleason评分（P=0.016）显著相关,其高表达与无生化复发生存率显著负相关（P =0.037）,但不能独立预测前列腺癌生化复发的危险度（危险比1.73,P=0.384）.结论 BCL9的上调表达与前列腺癌患者的早期诊断和恶性程度相关.

Objective B-cell lymphoma 9 （BCL9） as a co-activator for β-catenin-mediated transcription is highly expressed in tumors.The aim of our study is to investigate the expression of BCL9,and its clinicopathological significance in prostate cancer （PCa）.Methods Immunohistochemistry was conducted to analyze the expression of BCL9 in 98 PCa samples and 20 benign prostate hyperplasia （BPH） samples.The associations of BCL9 expression with clinicopathological features and prognosis in PCa patients were analyzed with various statistical methods,such as chi-square test,Kaplan-Meier method and log-rank test.Results The positive rate of BCL9 was 53.1% （52/98） in prostate cancer group,and 25.0% （5/20） in benign group （P =0.022）.In addition,BCL9 expression in PCa tissues was significantly associated with Gleason score （P =0.016）,and biochemical recurrence （P =0.020）.Moreover,Kaplan-Meier survival analysis showed that the higher expression of BCL9 was correlated with shorter biochemical recurrence-free survival （P =0.037）.However,BCL9 was not an independent prognostic predictor for biochemical recurrence-free survival in patients with PCa after the multivariate analysis was conducted （Hazard ratio =1.73,P =0.384）.Conclusion Our study demonstrates the up-regulation of BCL9 is associated with PCa＇s early diagnosis and malignant degree.